Can a malaria drug tame fatty liver? new trial aims to find out
NCT ID NCT07265297
First seen Jan 06, 2026 · Last updated May 13, 2026 · Updated 22 times
Summary
This study tests whether hydroxychloroquine, a drug used for malaria and autoimmune conditions, can improve liver health in people with nonalcoholic steatohepatitis (NASH). About 210 adults will take either a low or high dose of the drug or a placebo daily for one year. The goal is to see if the drug reduces liver inflammation and is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STEATOHEPATITIS, NONALCOHOLIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Taiwan University Hospital
RECRUITINGTaipei, Taiwan, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.